newsfilter
← Latest News
GlobeNewswire·

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities law claims against Vistagen Therapeutics, Inc. (NASDAQ: VTGN).
  • The firm reminds investors of the March 16, 2026 deadline to seek the role of lead plaintiff in the federal class action.
  • The complaint alleges Vistagen made false or misleading statements regarding the PALISADE-2 & PALISADE-3 clinical trials for fasedienol.
  • On December 17, 2025, Vistagen announced the PALISADE-3 study failed to meet its primary efficacy endpoint for treating social anxiety disorder.
  • Following the announcement, VTGN stock fell over 81% to open at $0.88 per share.
  • Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact partner James (Josh) Wilson.
  • Contact information for Wilson includes 877-247-4292 or 212-983-9330 (Ext. 1310).
  • The firm invites whistleblowers, former employees, & shareholders to share information regarding Vistagen's conduct.
  • The lead plaintiff must be an investor with the largest financial interest who is adequate & typical of the class.